High-dose erythropoietin and hypothermia for hypoxic-Ischemic encephalopathy: A phase II trial

Yvonne W. Wu, Amit M. Mathur, Taeun Chang, Robert C. McKinstry, Sarah B. Mulkey, Dennis E. Mayock, Krisa P. Van Meurs, Elizabeth E. Rogers, Fernando F. Gonzalez, Bryan A. Comstock, Sandra E. Juul, Michael E. Msall, Sonia L. Bonifacio, Hannah C. Glass, An N. Massaro, Lawrence Dong, Katherine W. Tan, Patrick J. Heagerty, Roberta A. Ballard

Research output: Contribution to journalArticlepeer-review

96 Scopus citations

Abstract

OBJECTIVE: To determine if multiple doses of erythropoietin (Epo) administered with abstract hypothermia improve neuroradiographic and short-term outcomes of newborns with hypoxic-ischemic encephalopathy. METHODS: In a phase II double-blinded, placebo-controlled trial, we randomized newborns to receive Epo (1000 U/kg intravenously; n = 24) or placebo (n = 26) at 1, 2, 3, 5, and 7 days of age. All infants had moderate/severe encephalopathy; perinatal depression (10 minute Apgar <5, pH <7.00 or base deficit ≥15, or resuscitation at 10 minutes); and received hypothermia. Primary outcome was neurodevelopment at 12 months assessed by the Alberta Infant Motor Scale and Warner Initial Developmental Evaluation. Two independent observers rated MRI brain injury severity by using an established scoring system. RESULTS: The mean age at first study drug was 16.5 hours (SD, 5.9). Neonatal deaths did not significantly differ between Epo and placebo groups (8% vs 19%, P = .42). Brain MRI at mean 5.1 days (SD, 2.3) showed a lower global brain injury score in Epo-treated infants (median, 2 vs 11, P = .01). Moderate/severe brain injury (4% vs 44%, P = .002), subcortical (30% vs 68%, P = .02), and cerebellar injury (0% vs 20%, P = .05) were less frequent in the Epo than placebo group. At mean age 12.7 months (SD, 0.9), motor performance in Epotreated (n = 21) versus placebo-treated (n = 20) infants were as follows: Alberta Infant Motor Scale (53.2 vs 42.8, P = .03); Warner Initial Developmental Evaluation (28.6 vs 23.8, P = .05). CONCLUSIONS: High doses of Epo given with hypothermia for hypoxic-ischemic encephalopathy may result in less MRI brain injury and improved 1-year motor function.

Original languageEnglish
Article numbere20160191
JournalPediatrics
Volume137
Issue number6
DOIs
StatePublished - Jun 2016

Fingerprint Dive into the research topics of 'High-dose erythropoietin and hypothermia for hypoxic-Ischemic encephalopathy: A phase II trial'. Together they form a unique fingerprint.

Cite this